[1] 张文忠. 155例肝硬化患者流行病学特征分析.实用肝脏病杂志,2012,15(1):55-56. [2] 麻树霖,陈征,刘晓峰. 血清MicroRNA作为生物学标记物对肝硬化诊断及预后判断研究进展.实用肝脏病杂志,2016,19(5):629-632. [3] 蔡均均,周静,韩涛,等.血清胱抑素C对肝硬化患者并发急性肾损伤的诊断价值.中华肝脏病杂志,2017,25(5):360-364. [4] Xirouchakis E,Marelli L,Cholongitas E,et al.Comparison of cystatin C and creatinine-based glomerular filtration rate formulas with Cr-51-EDTA clearance in patients with cirrhosis.Clin J Am Soc Nephrol,2012,44(3):2357-2359. [5] Dong Jin K,Hyun Seok K,Hyuk Soon C,et al.Serum cystatin C level is a useful marker for the evaluation of renal function in patients with cirrhotic ascites and normal serum creatinine levels.Korean J Hepatol,2011,17(2):130-138. [6] Finkenstedt A,Dorn L,Edlinger M,et al.Cystatin C is a strong predictor of survival in patients with cirrhosis:Is a cystatin C-based MELD better.Liver Int,2012,32(8):1211-1216. [7] 杨雪,邱春华. 血清胱抑素C在肝硬化患者肝功能评价中的意义. 中华实用诊断与治疗杂志,2011,25(3):248-250. [8] 赵芳,牛勇生,张东晟,等.肝硬化并发肾功能损害患者血清胱抑素C与肾功能指标相关性分析.中国基层医药,2014,21(11):1678-1680. [9] Dorde C,Milos T,Radmila O,et al.Role of cystatin C and renal resistive index in assessment of renal function in patients with liver cirrhosis.World J Gastroenterol,2014,20(21):6573-6579. [10] Nicolas R,Sandrine L.Evaluation of renal function in patients with cirrhosis:Where are we now World J Gastroenterol,2014,20(10):2533-2541. [11] Seo J,SeungK,Jun Yong P,et al.Predictors of refractory ascites development in patients with hepatitis B virus-related cirrhosis hospitalized to control ascitic decompensation.Yonsei Med J,2013,54(1):145-153. [12] Spodziej M,Rafalik M,Szymańska A,et al.Interaction of serum amyloid A with human cystatin C-assessment of amino acid residues crucial for hCC-SAA formation(part II). J Mol Recogn,2013,26(9):415-425. [13] Huang Z,Lin C,Fang J,et al.Acute kidney injury in hepatitis B-related acute-on-chronic liver failure without preexisting liver cirrhosis. Hepatol Int,2015,9(3):416-423. [14] Wong F.Acute kidney injury in liver cirrhosis:new definition and application.Clin Mol Hepatol,2016,22(4):415-422. [15] Gerbes A,Gülberg V,Bilzer M,et al.Evaluation of serum cystatin C concentration as a marker of renal function in patients with cirrhosis of the liver.Gut,2002,50(1):106-110. [16] Ahn HS,Kim YS,Kim SG,et al.Cystatin C is a good predictor of hepatorenal syndrome and survival in patients with cirrhosis who have normal serum creatinine levels. Hepatogastroenterology,2012,59(116):1168-1173. [17] Chung MY,Jun DW,Sung SA.Diagnostic value of cystatin C for predicting acute kidney injury in patients with liver cirrhosis. Korean J Hepatol,2010,16(3):301-307. [18] Slack AJ,McPhail MJW,Ostermann M,et al. Predicting the development of acute kidney injury in liver cirrhosis-An analysis of glomerular filtration rate,proteinuria and kidney injury biomarkers.Aliment Pharmacol Therap,2013,37(10):989-997. [19] Mindikoglu AL,Dowling TC,Weir MR,et al.Performance of chronic kidney disease epidemiology collaboration creatinine-cystatin C equation for estimating kidney function in cirrhosis. Hepatology,2014,59(4):1532-1542. [20] Barakat M,Khalil M.Serum cystatin C in advanced liver cirrhosis and different stages of the hepatorenal syndrome. Arab J Gastroenterology,2011,12(3):131-135. [21] 麻树霖,陈征,刘晓峰.血清MicroRNA作为生物学标记物对肝硬化诊断及预后判断研究进展.实用肝脏病杂志,2016,19(5):629-632. [22] 秦安东,曾东晓,刘娟,等. 血清胱抑素C检测对肝硬化患者肾功能损害的诊断价值.国际检验医学杂志,2013,34(19):2617-2619. [23] 胡超,沈世强,陈祖兵,等.肝硬化病人血清胱抑素C检测的临床意义.腹部外科,2012,25(3):177-178. [24] 张阳,杨自更,郭勇,等. 血清胱抑素C、尿微量白蛋白、尿β2-MG检测在肝硬化患者中的应用价值.标记免疫分析与临床,2014,21(6):677-678,682. |